UBM Stock Overview
A healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Ulisse Biomed S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.87 |
| 52 Week High | €1.95 |
| 52 Week Low | €0.84 |
| Beta | 0.62 |
| 11 Month Change | -8.79% |
| 3 Month Change | -15.34% |
| 1 Year Change | -47.47% |
| 33 Year Change | -76.11% |
| 5 Year Change | n/a |
| Change since IPO | -72.93% |
Recent News & Updates
Shareholder Returns
| UBM | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | -3.1% | 1.1% | -2.1% |
| 1Y | -47.5% | 7.6% | 11.9% |
Return vs Industry: UBM underperformed the Italian Biotechs industry which returned 9.9% over the past year.
Return vs Market: UBM underperformed the Italian Market which returned 15.9% over the past year.
Price Volatility
| UBM volatility | |
|---|---|
| UBM Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IT Market | 7.0% |
| 10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: UBM's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: UBM's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 8 | Nicola Basile | www.ulissebiomed.com |
Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases and HPV.
Ulisse Biomed S.p.A. Fundamentals Summary
| UBM fundamental statistics | |
|---|---|
| Market cap | €19.21m |
| Earnings (TTM) | -€6.97m |
| Revenue (TTM) | €420.92k |
45.6x
P/S Ratio-2.8x
P/E RatioIs UBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UBM income statement (TTM) | |
|---|---|
| Revenue | €420.92k |
| Cost of Revenue | €1.87m |
| Gross Profit | -€1.45m |
| Other Expenses | €5.52m |
| Earnings | -€6.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | -343.30% |
| Net Profit Margin | -1,655.06% |
| Debt/Equity Ratio | 1.8% |
How did UBM perform over the long term?
See historical performance and comparison